Background/Aims: Neurite outgrowth and synaptogenesis are critical steps for functional recovery after stroke. Resveratrol promotes neurite outgrowth and synaptogenesis, but the underlying mechanism is not well understood, although the Sonic hedgehog (Shh) signaling pathway may be involved. Given that resveratrol activates sirtuin (Sirt)1, the present study examined whether this is mediated by Shh signaling. Methods: Primary cortical neuron cultures were pretreated with drugs before oxygen-glucose deprivation/reoxygenation (OGD/R). Cell viability and apoptosis were evaluated with Cell Counting Kit 8 and by terminal deoxynucleotidyl transferase dUTP nick end labeling, respectively. Neurite outgrowth and synaptogenesis were assessed by immunocytochemistry and western blotting, which was also used to examine the expression of Sirt1 and Shh signaling proteins. Results: Resveratrol and the Smoothened (Smo) agonist purmophamine, which activates Shh signaling, increased the expression of growth-associated protein(GAP)-43, synaptophysin, Shh, Patched (Ptc)-1, Smo, glioma-associated oncogene homolog (Gli)-1, and Sirt1 were upregulated under these conditions. These effects were reversed by treatment with the Smo inhibitor cyclopamine, whereas the Sirt1 inhibitor sirtinol reduced the levels of Shh, Ptc-1, Smo, and Gli-1. Conclusions: Resveratrol reduces neuronal injury following OGD/R injury and enhances neurite outgrowth and synaptogenesis by activating Shh signaling, which in turn induces Sirt1.
anti-growth-associated protein (G P) 43 and anti-synaptophysin (SYP), monoclonal mouse anti-Sirt1, and polyclonal rabbit anti-Shh, -Ptch-1, -Smo, and -Gli-1 antibodies were from bcam (Cambridge, UK). Rabbit anti-glyceraldehyde 3-phosphate dehydrogenase (G PDH) antibodies were from Beyotime Institute of Biotechnology (Shanghai, China) and Goodhere Biotechnology (Hang hou, China). Normal goat serum (1 ) , and goat anti-rabbit lexa luor 488 and anti-mouse lexa luor 594 were from Beijing hongshan Golden Bridge Biotechnology (Beijing, China). Radioimmunoprecipitation assay (RIP ) lysis buffer, phenylmethanesulfonyl luoride (P S ), and 4, -diamidino-2-phenylindole (D PI) were from Beyotime Institute of Biotechnology (Jiangsu, China). Peroxidase-conjugated af iniPure goat anti-rabbit and antimouse IgG were from Proteintech Biotechnology ( uhan, China).
Primary cortical neuron culture
Neonatal male and female Sprague-Dawley rats (1 day old) provided by the xperimental nimal Center of Chongqing edical University (Chongqing, China) were used for primary cortical neurons cultures according to a modi ied version of a previously published protocol [15] . Brie ly, the cerebral cortex of rats was minced and incubated at 3 C for 3 min in a solution of 2 g/l papain. The tissue was washed in medium containing 1 BS and then passed through a 4 -mesh ilter. The dissociated cells were resuspended in complete medium composed of D / 12, 1 BS, 1 U/ml penicillin, and 1 mg/ml streptomycin, seeded on poly--lysine pre-coated plates at a density of 1 1 5 cells/cm 2 , and cultured at 3 C in humidi ied atmosphere of 95 air/5 CO 2 . fter cell attachment, the medium was replaced with neurobasal medium containing 2 B2 , .5 m glutamine, 1 U/ml penicillin, and 1 mg/ml streptomycin, with half of the volume of medium replaced every 2 days thereafter. rabinosylcytosine (5 g/ml) was added on day 3 after a 12-h incubation to purify neurons. Cells were used for experiments on day of culture. xperimental procedures were carried out with the approval of the nimal xperimental Committee of Chongqing edical University, Chongqing, China, and complied with relevant guidelines and laws.
OGD/R model
The OGD/R model was established according to previously described methods [15] to mimic cerebral artery occlusion and reperfusion injury. Brie ly, after three washes with -Hank's solution, neurons were maintained in -Hank's solution in a humidi ied anaerobic incubator (Thermo 3111; Thermo isher Scienti ic, altham, , US ) in an atmosphere of 94 N 2 , 1 O 2 , and 5 CO 2 at 3 C for 15 min. or reoxygenation, -Hank's solution was replaced with complete medium composed of neurobasal medium, 2 B2 , .5 m glutamine, 1 U/ml penicillin, and 1 mg/ml streptomycin and neurons were incubated in a humidi ied normoxic atmosphere of 5 CO 2 at 3 C for 24 h.
Drug treatment
To investigate whether resveratrol enhances neuronal viability after OGD/R injury, neuronal cultures were divided into ive groups 1) normal (neurons were cultured in complete medium without OGD/R); 2) control (neurons were subjected to OGD/R); 3) vehicle (neurons were cultured in complete medium containing ethanol [1.3 v/v] for 24 h before OGD/R); and 4) resveratrol pretreatment (neurons were cultured in complete medium containing different concentrations [1, 5 , and 2 mol/l] resveratrol for 24 h before OGD/R); and 5) blank (complete medium without neurons).
To determine whether the protective effects of resveratrol after OGD/R injury were exerted via Shh signaling, neuronal cultures were divided into six groups 1) normal (neurons were cultured in complete medium without OGD/R); 2) control (neurons were cultured in complete medium containing ethanol [1.3 v/v] for 24 h before OGD/R); 3) resveratrol (neurons were cultured in complete medium containing 5 mol/l resveratrol for 24 h before OGD/R); 4) resveratrol cyclopamine (neurons were cultured in complete medium containing 5 mol/l resveratrol and 5 mol/l cyclopamine for 24 h before OGD/R); 5) cyclopamine (neurons were cultured in complete medium containing 5 mol/l cyclopamine for 24 h before OGD/R); and ) purmorphamine (neurons were cultured in complete medium containing 3 mol/l purmorphamine for 24 h before OGD/R).
To investigate whether Shh signaling affects Sirt1 activation, neuronal cultures were divided into ive groups 1) normal (neurons were cultured in complete medium without OGD/R); 2) control (neurons were subjected to OGD/R without treatment); 3) resveratrol (neurons were cultured in complete medium containing 5 mol/l resveratrol for 24 h before OGD/R); 4) cyclopamine (neurons cultured in complete medium containing 5 mol/l cyclopamine for 24 h before OGD/R); and 5) purmorphamine (neurons were cultured in complete medium containing 3 mol/l purmorphamine for 24 h before OGD/R). To determine whether Sirt1 activation is associated with Shh signaling, neuronal cultures were divided into four groups 1) normal (neurons were cultured in complete medium without OGD/R); 2) control (neurons were subjected to OGD/R without treatment); 3) resveratrol (neurons were cultured in complete medium containing 5 mol/l resveratrol for 24 h before OGD/R); and 4) sirtinol (neurons were cultured in complete medium containing 1 mol/l sirtinol for 24 h before OGD/R).
Cell viability assay
Neuronal viability was assessed with Cell Counting Kit (CCK)-8. Brie ly, primary cortical neurons (approximately 8 /well) were seeded in poly--lysine-coated 9 -well plates with six replicates per group, and subjected to the above-described treatments. CCK-8 solution (1 l/1 l) was added to each culture well and neurons were incubated for 4 h at 3 C. bsorbance at 45 nm was measured with a microplate reader (Thermo Labsystems, Vantaa, inland). The experiment was repeated four times.
TUNEL assay
The TUN L assay was used to detect apoptotic neurons. Brie ly, neurons were ixed in 4 paraformaldehyde for 15 min, washed with phosphate-buffered saline (PBS), then incubated for 1 h at 3 C with anti-fading medium. Neurons were counterstained with anti-P2 antibody, and examined under a luorescence microscope (I 1; Olympus, Tokyo, Japan). The percentage of apoptotic cells was determined by counting the number of cells with nuclear condensation relative to the total number of cells for each experimental condition. The experiment was repeated three times.
Immunocytochemistry
Neurons were seeded on coverslips coated with poly--lysine and ixed with 4 paraformaldehyde for 3 min at room temperature, then washed three times with PBS and permeabili ed with .1 Triton -1 for 3 min at room temperature. fter three washes with PBS, cells were blocked with 1 normal goat serum for 3 min at 3 C, then incubated overnight at 4 C with the following primary monoclonal antibodies mouse anti-P2 (1 1 ) and anti-TuJ1 (1 2 ), and rabbit anti-G P43 (1 2 ) and anti-SYP (1 2 ). fter washes with PBS, cells were incubated with lexa luor 488 goat anti-rabbit or lexa luor 594 goat anti-mouse IgG (1 1 ) for 1 h at 3 C. The primary antibody was replaced with PBS in the negative control. Nuclei were counterstained with D PI for 5 min in the dark. Cells were examined with laser confocal microscope (Nikon, Tokyo, Japan). ach experiment was repeated three times.
Western blotting
To analy e cellular protein levels, primary cortical neurons were rinsed twice with ice-cold PBS, lysed in RIP lysis buffer containing 1 P S , and incubated on ice for 3 min. fter centrifugation at 12, g and 4 C for 1 min, the protein concentration was determined with the bicinchoninic acid assay. Protein samples were mixed with 5 loading buffer (1 4) and boiled for 1 min, and then resolved by 8 or 1 sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a polyvinylidene di luoride membrane ( illipore, Billerica, , US ). The membrane was blocked with 5 non-fat milk in PBS containing Tween 2 (2 1; PBST) for 2 h at room temperature and probed overnight at 4 C with the following primary antibodies diluted in 5 non-fat milk in PBST monoclonal rabbit anti-G P43 (1 5 ) and anti-SYP (1 3 ); monoclonal mouse anti-Sirt1 (1 5 ); polyclonal rabbit anti-Shh, -Ptch-1, -Smo, and -Gli-1 (1 1 ); and rabbit anti-G PDH (1 1 ) as a loading control. The membrane was washed with PBST and incubated with peroxidase-conjugated af iniPure goat anti-rabbit or anti-mouse IgG at 3 C for 1 h. Protein bands were detected by enhanced chemiluminescence and their intensities were analy ed with uantity One software (Bio-Rad, Hercules, C , US ). The gray ratio of the target protein to G PDH represented the expression level of the target protein. ach experiment was repeated three times.
Neurite outgrowth and synaptogenesis
To evaluate the neurite outgrowth and synaptogenesis, images obtained by laser confocal microscopy were analy ed with Image-Pro Plus v. . software ( edia Cybernetics, Rockville, D, US ). Neurite outgrowth was determined by counting the length of axons and number of dendrites. Synaptogenesis were determined by counting the number of synapses per neuron. Values are reported as the mean of at least three independent experiments with samples prepared in triplicate. 
Results

neonatal rats
Primary cortical neurons from neonatal rats expressed high levels of P2, as determined by immuno luorescence analysis ( ig. 1a c), con irming their identity as neurons.
The effects of resveratrol pretreatment on neuronal viability following OGD/R injury were investigated with the CCK-8 assay. Viability was decreased in the control ( .42 ± . 24), vehicle ( .429 ± . 2 ), and 1, 5, and 2 mol/l resveratrol ( .4 2 ± . 22, .515 ± . 38, and .423 ± . 21, respectively) groups relative to the normal ( .82 ± . 42) group ( ig. 2). There was no difference between the control and vehicle groups. Neuronal viability was higher in the resveratrol than in the control and vehicle groups, with the highest rate observed with 5 mol/l resveratrol treatment. These results indicate that resveratrol attenuates OGD/R injury of primary cortical neurons in a concentration-dependent manner. Since the most effective resveratrol concentration was 5 mol/l, this was used in subsequent experiments.
Our earlier studies showed that resveratrol reduced cerebral ischemic injury and improved neurological function in vivo by inhibiting apoptosis and oxidation [14, 15] and signaling in resveratrol-induced neurite outgrowth and synaptogenesis in primary cortical neurons following OGD/R injury. e irst evaluated the effects of resveratrol, cyclopamine, and purmorphamine on the viability of primary cortical neurons after ODG/R injury with the CCK-8 assay. Neurons in the control group decreased viability relative to the normal group ( .423 ± . 18 vs. .8 3 ±
. 39, P . 1) ( ig. 3t). Pretreatment with resveratrol or purmorphamine increased cell viability relative to the control group ( .52 ± . 24, P . 8 and .5 4 ± . 18, P . 13, respectively), although there was no difference between the resveratrol and purmorphamine groups (P .49 ). However, the effects of resveratrol on neuronal viability were inhibited in neurons cultured with cyclopamine alone ( .4 2 ± . 1 , P . 3) or cyclopamine combination with resveratrol ( .443 ± . 1 , P . 2 ). These results indicate that Shh signaling mediates the protective effects of resveratrol on neurons.
e next tested whether resveratrol, cyclopamine, or purmorphamine pretreatment affects apoptosis of primary cortical neurons after ODG/R injury with the TUN L assay. TUN L-positive cells were considered as apoptosis ( ig. 3a r, s). Double labeling for TUN L and P2 revealed apoptotic primary cortical neurons induced by ODG/R injury ( ig. 3a r); the percentage of TUN L / P2 cells was low in the normal group (1. 1 ± .18) ( ig. 3a c, s) and higher in the control group (2 .49 ± 1.55, P . ) as compared to the normal group 24 h after ODG/R. fter resveratrol or purmorphamine pretreatment, the percentage of TUN L / P2 cells (18.15 ± 1.31, P . 1 ; 19.83 ± 2.1 , P . 3 , respectively) was decreased relative to the control group, with no difference between the resveratrol and purmorphamine groups (P . 1 ) ( ig. 3g i, p s). However, cyclopamine combined with resveratrol (22.14 ± 2.18, P . 42) ( ig. 3p) or cyclopamine alone (29.98 ± 1.88, P . ) ( ig. 3q) abolished the effects of resveratrol. oreover, neurons treated with cyclopamine alone showed the highest fraction of TUN L / P2 cells. These results con irm that Shh signaling mediates the neuroprotective effects of resveratrol after ODG/R injury. e then investigated whether resveratrol, cyclopamine, and purmorphamine treatment affected neurite outgrowth in primary cortical neurons after OGD/R injury. Neurons were labeled with anti-TuJ1 antibody ( ig. 4a f) and the number and length of neurites were quanti ied ( ig. 4g, h). Neurons in the normal group had long and abundant neurites (133. ± 3.8 m and 11.42 ± .5 , respectively) ( ig. 4a, g, h). t 24 h after OGD/R injury, neurite length and number were decreased in the control relative to the normal group (5 .49 ± 4.13 . Pretreatment with resveratrol or purmorphamine rescued the decreases in neurite length and number (length 88.82 ± 5.4 m, P . 5 and .83 ± 4.24 m, P . 2 , respectively; number .48 ± .54, P . 8 and .1 ± .32, P . 1 , respectively) as compared to the control group ( ig. 4c, f h), with the values in the purmorphamine group lower than those in the resveratrol group (P . 2 ). However, the effects of resveratrol on neurite length and number were suppressed by treatment with cyclopamine alone (3 . 5 ± 2.28 m, P . and 3.4 ± .31, P . 3, respectively) or cyclopamine combined with resveratrol ( 2.8 ± 3.89 m, P . 1 and 5.52 ± .42, P . 45, respectively) ( ig. 4d, e, g, h). oreover, neurons treated with cyclopamine alone had the shortest and fewest neurites. These results indicate that resveratrol promotes neurite outgrowth via Shh signaling.
G P43 is a marker of axonal regeneration and synaptic plasticity [32, 33] , while SYP is a synaptic protein [34] . To investigate whether resveratrol, cyclopamine, or purmorphamine pretreatment affect synaptogenesis, we examined the expression of G P-43 and SYP after . and 3 .4 ± 3. 1, respectively) ( igs. 5 and l, s), cyclopamine (24. 5 ± 2. 1, P . and 23.98 ± 1. , respectively) ( igs. 5 and o, s), and purmorphamine (43.49 ± 3.22, P . and 5 .8 ± 5.89, respectively) ( igs. 5 and r, s) groups at 24 h after OGD/R injury were decreased relative to the normal group (89. 2 ± 2.39) ( igs. 5 and c, s). However, the fractions of G P43 / P2 and SYP / P2 neurons were higher in the resveratrol and purmorphamine as compared to the control group (resveratrol P . 1 and . 11; purmorphamine P . 2 and . 9), although there were no differences between these two treatments (P .11 and .292). hen neurons were treated with cyclopamine combined with resveratrol or purmorphamine, the percentages of G P43 / P2 and SYP / P2 cells were decreased relative to the control, resveratrol, and purmophamine groups (cyclopamine resveratrol P . 8 and . 1; cyclopamine purmorphamine P . and . 1). The lowest percentages were observed in the cyclopamine alone group.
western blot analysis revealed that G P-43 and SYP expression was increased in the resveratrol and purmorphamine groups and decreased in cyclopamine-treated cells (with or without resveratrol) relative to the control group. There were no differences in protein levels between resveratrol and purmophamine, and the levels were lowest in cells treated with cyclopamine alone ( igs. 5 and t, u). These results demonstrate that activation of Shh signaling by resveratrol following ODG/R injury induces the expression of proteins involved in synaptogenesis.
e investigated whether resveratrol pretreatment activated Shh signaling in neurons after ODG/R injury by western blotting. Shh, Ptc-1, Smo, and Gli-1 levels were higher in the control, resveratrol, cyclopamine resveratrol, and purmorphamine groups as compared to the normal group (P . 5; ig. ). There were no differences between the resveratrol and purmophamine groups, and the protein levels were highest in the former and lowest in the cyclopamine group. In contrast, the levels were decreased by cyclopamine treatment in the presence or absence of resveratrol as compared to the resveratrol and purmorphamine groups. These results con irm that Shh signaling is activated by resveratrol after OGD/R injury.
Interaction between Shh signaling and Sirt1
e have previously shown that resveratrol can decrease ischemic cerebral injury; promote neuronal survival, neurite outgrowth, and synaptogenesis; enhance proliferation of NSCs, and induce neuronal differentiation of bone mesenchymal stem cells by activating Shh signaling [15, 1 , 23] . Resveratrol is a small-molecule activator of Sirt1; many studies have linked the health bene its of resveratrol to modulation of Sirt1 activity [29, 3 ] . e therefore examined whether Shh signaling interacts with Sirt1 to mediate the effects of resveratrol.
t 24 h after OGD/R injury, Sirt1 expression was upregulated in the control as compared to the normal group ( ig. 8a, b). Resveratrol or purmorphamine pretreatment increased Sirt1 expression, which was higher in the resveratrol than in the purmorphamine group. However, Sirt1 expression was reduced in the cyclopamine as compared to the resveratrol and purmophamine groups. These results demonstrate that activation of Shh signaling alters Sirt1 expression. e also found that inhibiting Sirt1 with sirtinol reduced the protein levels of Shh, Ptc-1, Smo, and Gli-1 relative to the control and resveratrol groups ( ig. 8c, g). These 
Discussion
The results of the present study showed that resveratrol pretreatment increased viability, reduced apoptosis, and enhanced neurite outgrowth and synaptogenesis of neurons after ODG/R injury in vitro. These effects were mediated via activation of Shh signaling and were abolished by treatment with cyclopamine, a Smo receptor inhibitor. Conversely, activation of Shh signaling by purmophamine, a Smo receptor agonist, produced effects similar to resveratrol. In addition, resveratrol and purmophamine increased, whereas cyclopamine decreased, Sirt1 protein expression. Sirtinol, a Sirt1 inhibitor, suppressed the expression of Shh, Ptc-1, Smo, and Gli-1. Taken together, these indings provide evidence that resveratrol decreases neuronal injury and promotes neurite outgrowth and synaptogenesis following OGD/R injury in vitro via activation of Shh signaling and Sirt1 and Shh may interact with Sirt1.
It was previously reported that 1 resveratrol induced neurite outgrowth in Neuro2a cells via activation of P kinase ( PK) [13] . Others have found that 1 and 2 resveratrol enhanced nerve growth factor-induced neurite outgrowth in PC12 cells via Sirt1 activation [35] . Similar indings were reported in cultured diabetic neurons treated with .1 3 resveratrol, whereas 5 mg/kg resveratrol reversed thermal hypoalgesia and prevented intraepidermal nerve iber loss in strepto otocin-induced diabetic rats by increasing PK expression and phosphorylation and improving mitochondrial function [11] . Resveratrol also restored the inhibitory effects of microglial over-activation on dendrite sprouting and outgrowth of hippocampal neurons [3 ] . Our present study showed that 5 resveratrol pretreatment promoted neurite outgrowth and synaptogenesis in primary OGD/R injury cortical neurons via activation of the Shh signaling pathway. However, 5 resveratrol did not prevent amyloid--induced neurotoxicity or enhance neurite outgrowth in N2a cells [12] , and failed to restore neurite outgrowth defects in -de icient PC12 cells [3 ] . These studies indicate that the effects of resveratrol on neurite outgrowth vary according to physiological or pathological state. lthough growthing reports and our studies showed that resveratrol has neuroprotective or neurorestorative effects, the mechanism of how resveratrol promotes neurite outgrowth and synaptogenesis is unknown but is important understand in order to manipulate the neurite outgrowth microenvironment to enhance repair and regeneration.
Shh signaling plays a critical role in embryonic development and central nervous system patterning. It is also required for neurite outgrowth, axon guidance, and synaptogenesis in the developing, postnatal, and adult brains. Shh signaling is only activated in the normal adult nervous system in disorders such as stroke [2 - [4 ] , l heimer's disease [4 , 48] , traumatic brain, spinal cord, or peripheral nerve traumatic injury [49 52], subarachnoid hemorrhage [53] , and epilepsy [54, 55] . In cerebral ischemic injury, cerebrolysin, bone marrow stromal cells, and purmorphamine enhance activation of the Shh signaling pathway to promote brain plasticity and functional recovery [2 , 22, 39] . On the contrary, cyclopamine treatment aggravated brain damage in acute ischemic stroke [5 ] . In rat and common marmosets models of Parkinson's disease induced by -hydroxydopamine or 1-methyl-4-phenyl-1, 2,3, -tetrahydropyridine, Shh mitigated neurotoxicity in nigral dopaminergic neurons, reduced apomorphine-and amphetamineinduced rotation and forelimb akinesia, partly preserved dopaminergic axons in the striatum, and repaired nigrostriatal projections [41] . HB1. 3.Olig2 cells treated with Shh protein and transplanted into L5 L spinal in a mouse model of LS delayed the onset of clinical symptoms and extended lifespan [45] . HD is characteri ed by neuronal dysfunction and progressive loss of dopamine-and cyclic expressing medium-si ed spiny neurons in the striatum; Shh increased human pluripotent stem cell differentiation into striatal projection neurons [5 ] , while purmorphamine induced the differentiation of D RPP-32-positive striatal NSCs via Shh signaling, which was blocked by cyclopamine [4 ] . l heimer's disease is caused by the progressive degeneration of cholinergic neurons in the forebrain; in basal forebrain cultures, Shh increased the number of these neurons [4 ] . In addition, human embryonic stem cells or induced pluripotent stem cell-derived primitive neuroepithelial cells treated with Shh or purmorphamine and cocultured with human astrocytes differentiated into basal forebrain cholinergic neurons [58] .
In a mechanical stretch model of reactive astrogliosis, Shh promoted neurite outgrowth in a concentration-dependent manner, an effect that was inhibited by cyclopamine and activated by oxysterol 2 (S)-hydroxycholesterol, both of which modulate Smo activity [59] . In adult dorsal root ganglia neurons, expression of Shh and its receptors was upregulated after axotomy; however, Shh de iciency inhibited axonal outgrowth and branching in cultured adult sensory neurons [5 ] . Shh has also demonstrated neuroprotective effects following crush injury of the cavernous nerve [49] . Our previous study showed that cyclopamine treatment decreased the viability and proliferation of NSCs following OGD/R injury [1 ] and increased ischemic cerebral injury after stroke [15] . Thus, our results are consistent with previous reports that activation of Shh signaling plays a critical neuroprotective and neurorestorative role following brain injury. It remains unclear how resveratrol activates Shh signaling. One possibility is that it increases the expression of Shh or its receptors. However, resveratrol is a activator of Sirt1, and some studies have proposed an allosteric mechanism in which the binding of resveratrol to the N terminal domain of Sirt1 induces a conformational change that promotes tighter binding between Sirt1 and its substrate [ , 1], implying that resveratrol is an isoformselective sirtuin activator. However, another study suggested a substrate-dependent Sirt1 activation mechanism in which resveratrol acts to stabili e protein-substrate interaction rather than as an allosteric modulator [29] . Here, our study for the irst time showed that the Smoothened (Smo) agonist purmophamine increased the expression of Sirt1, the Smoothened (Smo) antagonist cyclopamine decreased the expression of Sirt1, and the Sirt1 inhibitor sirtinol decreased the expressions of Shh, Ptc-1, Smo, and Gli-1proteins. Tiberi et al. reported that a Sirt1 complex inhibited the Shh signaling in normal and oncogenic neural development [31] . Kong and Yang et al. show that Notch signaling tunes neural progenitor responses to Shh by regulating traf icking of the Shh receptor Patched1 and downstream effector Smoothened to primary cilia. However, Notch can interact with Sirt1 via Hes1 [ 2] . Therefore, whether Sirt1 is a downstream or upstream target of the Shh signaling activated by resveratrol, or Sirt1 inhibits or activates the Shh signaling remains to be further determined.
Brain derived-nerve neurotrophic factor (BDN ) is a neurotrophic factor widely distributed in the central and peripheral nervous system. It is shown to promote neuronal growth, survival, and injury repair and plays signi icant role in neurogenesis and neurodegenerative diseases [3] [4] [5] . It was reported that resveratrol can signi icantly promote the recovery of motor function in rats after cerebral ischemic injury [ ], decrease hippocampal damage and improve the cognitive de icits in a rat model of vascular dementia [ ], decrease hippocampal apoptosis and promote synaptic plasticity and improve cognitive impairment in strepto otocin-induced diabetic rats [ 8] , which is likely related to the upregulation of the BDN signaling pathway . Shh is a key regulator of multiple pathways during development and in the adult, the BDN pathway may be one of several regulated by Shh to promote neurite outgrowth. He et al. reported that Shh promotes neurite outgrowth in primary cortical neurons at least partially through modulating BDN expression [ 9] . hou et al. reported that gene expression of BDN was decreased in dopaminergic neurons by crossing D Tcre (dopamine transporter) mice with Smo(loxP/loxP) knockout mice [ ]. In autism spectrum disorder , there was signi icant correlation between serum levels of BDN and Shh [ 1, 2] . In normal and regenerating cavernous nerves, Shh promote regeneration of cavernous nerves via regulating expression of BDN [ 3] to the protective effects of BDN against mitochondrial inhibitor 3-Nitropropionic acid neurotoxicity [ 4, 5] . Therefore, whether BDN is a downstream or upstream target of the Shh signaling activated by resveratrol, or BDN inhibits or activates the Shh signaling remains to be further determined. It was previously reported that resveratrol pretreatment 14 days, days, 48h, or 2h before cerebral ischemic injury could protect against ischemic cerebral injury in vivo [ -9] . Resveratrol, administered for 4 days and 2h prior to ischemia-reperfusion injury and/or days later in the ileum of rats, had a neuroprotective effect [8 ] . Treatment with resveratrol at the onset of reperfusion or up to 3 h and h or 24 h or post-acute delivery after reperfusion in rodent cerebral ischemic models also showed neuroprotective or neurorestorative effects [81] [82] [83] [84] [85] . Others have reported that resveratrol, added 2 h before and 24 h after ioni ing radiation, reversed the irradiation-induced decline of neural stem cells in murine hippocampal tissue cultures [8 ] . oreover, resveratrol can promote neurite outgrowth and synaptogenesis in Neuro2a cells, primary neurons, l heimer's disease neurons, and sensory neurons derived from diabete rats in vitro and prevent axonal degeneration after injury [13, 8 -89] . Our previous and present studies also showed that resveratrol pretreatment for days before stroke in vivo or 24h before OGD/R injury in vitro has neuroprotective or neurorestorative effects [14, 15] . These studies indicated that pre-, post-, and delayed posttreatment with resveratrol showed neuroprotective or neurorestorative effects. However, there are many questions to be further illuminated. or example, whether does pretreatment with resveratrol, purmophamine and/or cyclopamine already affect neurite outgrowth, the level of G P43, synaptophysin and Shh signaling molecules before ODG/R and cerebral ischemic injury in vitro and vivo? Can shorter resveratrol pretreatment increase Shh signaling in the neuron in vitro or brain in vivo and will it be neuroprotective or neurorestorative? Do resveratrol also enhance neurite outgrowth and synaptogenesis when administered after OGD/R or ischemic injury in vivo or vitro and will it involve Shh signaling? In the future, we will further investigate above questions.
In summary, the results presented here demonstrate that the Shh signaling pathway mediates, at least partly, the effects of resveratrol to increase viability, prevent apoptosis, and enhance neurite outgrowth and synaptogenesis in neurons following OGD/R injury in vitro.
e also provide the irst evidence that Shh signaling may act on Sirt1 to exert these effects. However, does resveratrol act directly on Shh or its recepors? Or is the effect of resveratrol on Shh signaling mediated through Sirt1 or BDN or another mechanism? It is further elaborated in vivo and vitro. 
